In Module 1 of this micro learning, developed by experts Prof. Peter R. Galle and Dr Aiwu Ruth He, you'll learn about the safety and efficacy of immunotherapy (IO) for hepatocellular carcinoma (HCC) and how to implement IO treatments for patients with HCC in clinical practice.

The content includes a short animated video, downloadable resources, and an assessment to test your knowledge.

When you're ready, move on to Module 2: The Use of Immunotherapy in HCC: In-depth Subgroup Analyses and Challenges.

 

Efficacy of IO for HCC

Learn how to:

  • Recognise the efficacy of IO and IO combinations
  • Understand the survival curve when assessing IO treatment
  • Know where IO and IO combinations sit in the treatment landscape for patients with HCC

 

Safety of IO for HCC

Learn how to:

  • Recognise the immune-related adverse events (irAEs) and potential additive or synergistic toxicities associated with IO combinations
  • Know how to identify and manage these AEs early on

Clinical Takeaways

 

  • IO, and in particular IO combinations, are effective treatments for patients with advanced HCC

  • Survival analysis for IO treatment shifts from median overall survival (OS) to landmark analysis

  • IO and IO combinations may result in inflammatory side effects, known as irAEs. Most of these AEs can be treated with steroids

Aiwu Ruth He, MD, PhD is a Professor of Medicine at Columbia University Medical Center. She earned her MD from the Xiangya School of Medicine at Central South University and her PhD in Biochemistry from East Carolina University’s Brody School of Medicine. Dr He completed her postdoctoral training at the National Institutes of Health under the mentorship of Dr Simeon Taylor, followed by an internal medicine residency at the Brody School of Medicine and a Hematology/Oncology fellowship at Georgetown University Hospital.

 

Dr He is a recognized leader in liver cancer research and patient care, with a primary focus on developing innovative therapeutics for hepatocellular carcinoma (HCC) and biliary tract cancer (BTC). 

 

She is deeply committed to a programmatic, multidisciplinary approach to clinical practice, ensuring optimal outcomes for her patients across the continuum of care.

 

Outside of her clinical duties, Dr He serves as the Director of Hepatobiliary Cancers in the Department of Medicine, Division of Hematology and Oncology, as well as the Director of Liver Transplant Oncology at the Center for Liver Disease and Transplantation. In these roles, she oversees clinical research on hepatobiliary cancers.

 

For a list of publications, please visit:

https://pubmed.ncbi.nlm.nih.gov/?term=he%2C+AR+or+He%2C+aiwu

Prof. Aiwu Ruth He has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, BMS, Boston Scientific, Eisai, Genentech and Merck.

Programme summary
Take the micro learning now
Other episodes of this series
The Use of Immunotherapy in HCC

The Use of Immunotherapy in HCC

Module 1: Efficacy and Safety

Current Module
The Use of Immunotherapy in HCC

The Use of Immunotherapy in HCC

Module 2: In-depth Subgroup Analyses and Challenges

The expanding role of immunotherapy in HCC

The expanding role of immunotherapy in HCC

Module 3: Combining locoregional and systemic treatments in intermediate HCC

Share this programme
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Accreditation and Endorsement
EACCME
This course has been accredited by EACCME® for ECMEC®.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update
Oncology 
Highlights from ASCO 2025

Coming Soon: Expert insights on the latest data 

Experts
Prof. Mark Socinski, Dr Elizabeth Smyth, Dr Paolo Tarantino, Dr Domenica Lorusso, Prof. Gerhardt Attard
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • clock 1 MIN
  • calendar May 2025

The oncogene-addicted NSCLC supported through an Independent Educational Grant from Bayer with all other updates supported by COR2ED
symposium Symposium
Oncology 
ER+/HER2- metastatic breast cancer: Highlights from ESMO Breast Cancer 2025 Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer

Experts
Prof. Wolfgang Janni, Prof. Sherko Kümmel, Prof. Michail Ignatiadis
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Serie de podcasturi referitoare la gestionarea trombozei

Experți de renume din domeniul medical își împărtășesc perspectivele. Navigați în secțiuni pentru a selecta un episod al podcastului 

Experts
Prof. Dimitrios Tsakiris, Dr Lars Asmis, Prof. Jerzy Windyga, Prof. Daniel Bolliger
  • download Downloadable
    Resources
  • clock 21 MIN
  • calendar May 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
video Video
Oncology Hemato-oncology 
Optimising the sequence of novel therapies from early relapse in multiple myeloma

Improving the survival of patients with relapsed/refractory multiple myeloma

Experts
Prof. Hermann Einsele, Prof. Evangelos Terpos
  • download Downloadable
    Resources
  • clock 2 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
animated-video Animated Video
Oncology 
BRAF V600E mutated NSCLC: The evolving treatment landscape

Expert insights into personalised treatment strategies in BRAF-mutated NSCLC

Experts
Prof. Amanda Tufman
Endorsed by
BRAF Bombers ICAN international cancer advocacy network Biomarker Collaborative
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar May 2025

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
podcast Podcast
Oncology 
Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC)

Chemotherapy strategies that matter

Experts
Prof. Shubham Pant, Prof. Efrat Dotan
Endorsed by
DiCE ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from Ipsen USA